NASDAQ:MEDS

TRxADE HEALTH Stock Forecast, Price & News

$5.35
-1.32 (-19.79 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.01
$6.10
50-Day Range
$3.11
$6.67
52-Week Range
$3.10
$10.82
Volume4.29 million shs
Average Volume1.88 million shs
Market Capitalization$43.30 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14
30 days | 90 days | 365 days | Advanced Chart
Receive MEDS News and Ratings via Email

Sign-up to receive the latest news and ratings for TRxADE HEALTH and its competitors with MarketBeat's FREE daily newsletter.


TRxADE HEALTH logo

About TRxADE HEALTH

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.41 out of 5 stars

Retail/Wholesale Sector

142nd out of 401 stocks

Drugs, Proprietaries, & Sundries Industry

7th out of 14 stocks

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











TRxADE HEALTH (NASDAQ:MEDS) Frequently Asked Questions

Is TRxADE HEALTH a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TRxADE HEALTH in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRxADE HEALTH stock.
View analyst ratings for TRxADE HEALTH
or view top-rated stocks.

What stocks does MarketBeat like better than TRxADE HEALTH?

Wall Street analysts have given TRxADE HEALTH a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TRxADE HEALTH wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting TRxADE HEALTH?

TRxADE HEALTH saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 3,800 shares, an increase of 18.8% from the May 13th total of 3,200 shares. Based on an average daily trading volume, of 3,080,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.1% of the company's stock are sold short.
View TRxADE HEALTH's Short Interest
.

When is TRxADE HEALTH's next earnings date?

TRxADE HEALTH is scheduled to release its next quarterly earnings announcement on Monday, July 26th 2021.
View our earnings forecast for TRxADE HEALTH
.

How were TRxADE HEALTH's earnings last quarter?

TRxADE HEALTH, Inc. (NASDAQ:MEDS) issued its earnings results on Sunday, April, 25th. The company reported ($0.08) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.05. The business had revenue of $3.05 million for the quarter, compared to analysts' expectations of $2.10 million. TRxADE HEALTH had a negative net margin of 18.74% and a negative trailing twelve-month return on equity of 35.59%.
View TRxADE HEALTH's earnings history
.

How has TRxADE HEALTH's stock price been impacted by COVID-19 (Coronavirus)?

TRxADE HEALTH's stock was trading at $4.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MEDS stock has increased by 7.9% and is now trading at $5.35.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MEDS?

3 Wall Street analysts have issued twelve-month price targets for TRxADE HEALTH's stock. Their forecasts range from $10.00 to $15.00. On average, they expect TRxADE HEALTH's share price to reach $12.50 in the next year. This suggests a possible upside of 133.6% from the stock's current price.
View analysts' price targets for TRxADE HEALTH
or view top-rated stocks among Wall Street analysts.

Who are TRxADE HEALTH's key executives?

TRxADE HEALTH's management team includes the following people:
  • Mr. Surendra K. Ajjarapu, Founder, Chairman, CEO, Treasurer & Sec. (Age 50, Pay $295.42k)
  • Mr. Prashant Patel, Founder, Pres, COO & Director (Age 47, Pay $150.41k)
  • Mr. Howard A. Doss, Chief Financial Officer (Age 67, Pay $90.43k)
  • Dr. Ramesh Kenchappa, Chief Scientific Officer
  • Mr. David M. Saslow, Inhouse Counsel
  • Mr. Jariel Morales, Exec. VP

Who are some of TRxADE HEALTH's key competitors?

What other stocks do shareholders of TRxADE HEALTH own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRxADE HEALTH investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Biocept (BIOC), iBio (IBIO), Ollie's Bargain Outlet (OLLI), OPKO Health (OPK), Alto Ingredients (PEIX), PharmaCyte Biotech (PMCB), Tiziana Life Sciences (TLSA) and Trevena (TRVN).

What is TRxADE HEALTH's stock symbol?

TRxADE HEALTH trades on the NASDAQ under the ticker symbol "MEDS."

Who are TRxADE HEALTH's major shareholders?

TRxADE HEALTH's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.37%) and International Assets Investment Management LLC (0.07%). Company insiders that own TRxADE HEALTH stock include Donald G Fell, Michael L Peterson and Prashant Patel.
View institutional ownership trends for TRxADE HEALTH
.

Which major investors are buying TRxADE HEALTH stock?

MEDS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and International Assets Investment Management LLC.
View insider buying and selling activity for TRxADE HEALTH
or or view top insider-buying stocks.

How do I buy shares of TRxADE HEALTH?

Shares of MEDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRxADE HEALTH's stock price today?

One share of MEDS stock can currently be purchased for approximately $5.35.

How much money does TRxADE HEALTH make?

TRxADE HEALTH has a market capitalization of $43.30 million and generates $17.12 million in revenue each year.

How many employees does TRxADE HEALTH have?

TRxADE HEALTH employs 43 workers across the globe.

What is TRxADE HEALTH's official website?

The official website for TRxADE HEALTH is www.trxade.com.

Where are TRxADE HEALTH's headquarters?

TRxADE HEALTH is headquartered at 3840 Land O' Lakes Blvd., Land O' Lakes FL, 34639.

How can I contact TRxADE HEALTH?

TRxADE HEALTH's mailing address is 3840 Land O' Lakes Blvd., Land O' Lakes FL, 34639. The company can be reached via phone at 800-261-0281 or via email at [email protected]


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.